Kevin Black

Professor of Psychiatry

Additional Titles & Roles

  • Professor of Neurology, of Radiology, and of Neuroscience

Education & Training

  • Fellowship: Movement Disorders and Neuroimaging: Washington University, St. Louis, MO, 1996
  • Residency: Washington University, St. Louis, MO, 1994
  • MD: Duke University, Durham, NC, 1990
  • BS: Mathematics: Brigham Young University, Provo, UT, 1986

Major Awards

  • Certification in Behavioral Neurology and Neuropsychiatry, United Council for Neurologic Subspecialties (UCNS), 2006,, 2016
  • Listed in Castle Connolly’s American’s Top Doctors, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016
  • Elected by his peers for inclusion in Best Doctors in America®, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016
  • Named a Fellow of the American Neuropsychiatric Association, 2006
  • Hope Award from the St. Louis chapter of the HDSA (Huntington Disease Society of America), 2006
  • American College of Neuropsychopharmacology (ACNP) / Bristol-Myers Squibb Travel Award, 2001

Areas of Clinical Interest

Tourette syndrome (TS) and other tic disorders, neuropsychiatry of Parkinson’s disease and dystonia, Huntington’s disease, tardive dyskinesia, catatonia, psychogenic or atypical movement disorders

Research Interests

Neuroimaging methods development including pharmacological fMRI.
Tourette syndrome (TS) and other tic disorders.
Neuroimaging and clinical studies in TS and other movement disorders.
Methods development for analyzing results of deep brain stimulation (DBS).

Visit lab website

Key Publications

See more publications

Funded Research Projects

NIMH (PI):The New Tics study: A novel approach to pathophysiology and cause of tic disorders
Michael J. Fox Foundation for Parkinson’s Research (PI):Dopamine buffering capacity measured by phMRI as a novel biomarker of disease progression in PD
NIDDK (Significant Contributor):Early Predictors of Brain Health and Development in Youth with T1DM
Tourette Association of America (Significant Contributor):Testing a Pathophysiological Model of Complex Tics
ACADIA Pharmaceuticals (site PI): An Open-label, 8-Week Study of Safety and Efficacy for Adjunctive Pimavanserin Treatment in Adults With Parkinson’s Disease and Inadequately Controlled Depression (ACP-103-048)